PMID- 10463607
OWN - NLM
STAT- MEDLINE
DCOM- 19990916
LR  - 20111117
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 59
IP  - 16
DP  - 1999 Aug 15
TI  - Identification of a gene coding for a protein possessing shared tumor epitopes
      capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer
      patients.
PG  - 4056-63
AB  - Genes encoding tumor epitopes that are capable of inducing CTLs against
      adenocarcinomas and squamous cell carcinomas, two major human cancers
      histologically observed in various organs, have rarely been identified. Here, we 
      report a new gene from cDNA of esophageal cancer cells that encodes a shared
      tumor antigen recognized by HLA-A2402-restricted and tumor-specific CTLs. The
      sequence of this gene is almost identical to that of the KIAA0156 gene, which has
      been registered in GenBank with an unknown function. This gene encodes a Mr
      140,000 protein that is expressed in the nucleus of all of the malignant tumor
      cell lines tested and the majority of cancer tissues with various histologies,
      including squamous cell carcinomas, adenocarcinomas, melanomas, and leukemia
      cells. However, this protein was undetectable in the nucleus of any cell lines of
      nonmalignant cells or normal tissues, except for the testis. Furthermore, this
      protein was expressed in the cytosol of all of the proliferating cells, including
      normal cells and malignant cells, but not in normal tissues, except for the
      testis and fetal liver. Two peptides of this protein were recognized by
      HLA-A2402-restricted CTLs and were able to induce HLA-A24-restricted and
      tumor-specific CTLs from peripheral blood mononuclear cells of most of HLA-A24+
      cancer patients tested, but not from peripheral blood mononuclear cells of any
      healthy donors. These peptides may be useful in specific immunotherapy for
      HLA-A24+ cancer patients with various histological types.
FAU - Yang, D
AU  - Yang D
AD  - Cancer Vaccine Development Division, Kurume University Research Center for
      Innovative Cancer Therapy, Kurume University School of Medicine, Japan.
FAU - Nakao, M
AU  - Nakao M
FAU - Shichijo, S
AU  - Shichijo S
FAU - Sasatomi, T
AU  - Sasatomi T
FAU - Takasu, H
AU  - Takasu H
FAU - Matsumoto, H
AU  - Matsumoto H
FAU - Mori, K
AU  - Mori K
FAU - Hayashi, A
AU  - Hayashi A
FAU - Yamana, H
AU  - Yamana H
FAU - Shirouzu, K
AU  - Shirouzu K
FAU - Itoh, K
AU  - Itoh K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A24 Antigen)
SB  - IM
MH  - Antigens, Neoplasm/*genetics/immunology
MH  - Base Sequence
MH  - Cytotoxicity, Immunologic/genetics
MH  - Epitopes/genetics
MH  - Gene Expression Regulation, Neoplastic/immunology
MH  - HLA-A Antigens/*immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Lymphocyte Activation/genetics
MH  - Molecular Sequence Data
MH  - Neoplasms/*genetics/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
EDAT- 1999/08/27 00:00
MHDA- 1999/08/27 00:01
CRDT- 1999/08/27 00:00
PHST- 1999/08/27 00:00 [pubmed]
PHST- 1999/08/27 00:01 [medline]
PHST- 1999/08/27 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1999 Aug 15;59(16):4056-63.